Loading
A phase 1/2 trial of Rilvegostomig in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC is a phase 1/2 interventional study registered as NCT04995523 by AstraZeneca, with 212 participants enrolled, started 2021-09-14 and due to reach its primary completion in 2026-08-28. Interventions recorded: AZD2936.
Shares Rilvegostomig, AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.